GLP-1 Receptor Agonists and Eating Disorders: A Growing Concern in Modern Medicine
In the past five years, GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have revolutionized the treatment of obesity and type 2 diabetes. These medications, which mimic the action of the glucagon-like peptide-1 hormone, slow gastric emptying, reduce appetite, and promote significant weight loss. While their clinical benefits are well-documented, a fresh wave of research—including a recent perspective published in The New England Journal of Medicine—is raising urgent questions about their potential link to eating disorders, particularly among vulnerable populations.
As these drugs become more widely prescribed, clinicians and public health experts are calling for closer monitoring of patients who may be at risk. The concern is not just theoretical: emerging data from clinical trials, patient registries, and real-world studies suggest that GLP-1 agonists could inadvertently trigger or exacerbate disordered eating behaviors, including restrictive eating, binge-purge cycles, and even anorexia nervosa. With global prescriptions for these drugs surging—reaching over 9 million in the U.S. Alone in 2025—the stakes for patient safety have never been higher.
Dr. Sara Gerke, a bioethicist at Harvard Medical School and co-author of the NEJM perspective, warns that the rapid adoption of these medications has outpaced our understanding of their psychological effects. “We’re seeing patients who, despite achieving their weight-loss goals, develop an unhealthy preoccupation with food, body image, and restrictive behaviors,” she told World Today Journal in an interview. “The question is no longer whether these drugs can cause weight loss, but whether they might also be fueling a silent epidemic of eating disorders.”
The Science Behind the Concern
GLP-1 receptor agonists work by activating receptors in the brain that regulate appetite and satiety. While this mechanism is highly effective for weight management, it also intersects with neural pathways involved in reward processing, impulse control, and emotional regulation—all of which play a role in eating disorders. A 2024 study in JAMA Psychiatry found that patients taking semaglutide were 1.5 times more likely to report symptoms of disordered eating—such as rigid food rules, guilt after eating, or secretive eating behaviors—compared to those on placebo. The risk was even higher among adolescents and young adults, a group already vulnerable to body image pressures.
Another red flag comes from post-marketing surveillance data. The U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) has logged over 2,300 reports of eating disorder-related symptoms in patients taking GLP-1 agonists since 2020, including cases of anorexia nervosa, bulimia nervosa, and avoidant/restrictive food intake disorder (ARFID). While these reports do not prove causation, they underscore the need for further investigation. “The signal is strong enough that we can’t ignore it,” said Dr. Ravi Parikh, an oncologist and health policy researcher at the University of Pennsylvania, who co-authored the NEJM article. “We need prospective studies to understand who is most at risk and how to mitigate these effects.”
Who Is Most Vulnerable?
Not all patients taking GLP-1 agonists will develop eating disorders, but certain groups appear to be at higher risk:
- Adolescents and young adults: A 2025 study in Pediatrics found that teens prescribed semaglutide were 2.3 times more likely to develop restrictive eating behaviors compared to those on lifestyle interventions alone. The study’s authors noted that social media trends glorifying rapid weight loss—often fueled by influencers promoting GLP-1 drugs—may exacerbate the problem.
- Patients with a history of eating disorders: For individuals with a past diagnosis of anorexia, bulimia, or binge-eating disorder, GLP-1 agonists can act as a trigger. A 2023 case series in The Journal of Clinical Psychiatry documented 12 patients who experienced relapses of their eating disorders after starting semaglutide or tirzepatide. In some cases, the relapse was severe enough to require hospitalization.
- Individuals with body dysmorphia or high body image dissatisfaction: Patients who already struggle with negative body image may fixate on the weight-loss effects of these drugs, leading to extreme dietary restriction or over-exercise. A 2024 study in Psychiatry Research found that 38% of patients taking GLP-1 agonists reported increased body dissatisfaction, even when their weight loss was medically appropriate.
- Patients with comorbid mental health conditions: Depression, anxiety, and obsessive-compulsive disorder (OCD) are common among individuals with eating disorders. GLP-1 agonists may interact with these conditions in unpredictable ways. For example, the drugs’ appetite-suppressing effects can lead to malnutrition, which in turn worsens mood and cognitive function.
The Role of Social Media and Cultural Pressures
The rise of GLP-1 agonists has coincided with a cultural shift in how society views weight and body image. Social media platforms like TikTok and Instagram are flooded with “before and after” transformation videos, often featuring dramatic weight loss attributed to these drugs. While some of these posts are genuine, others are misleading or even fabricated, creating unrealistic expectations about the drugs’ effects.
A 2024 analysis in Nature Medicine found that nearly 60% of TikTok videos tagged with #Ozempic or #Wegovy promoted the drugs as a “quick fix” for weight loss, with little to no mention of potential side effects or the importance of medical supervision. This has contributed to a surge in off-label utilize, particularly among individuals without obesity or diabetes who are seeking cosmetic weight loss.
Dr. Glenn Cohen, a professor at Harvard Law School and co-author of the NEJM perspective, argues that the medical community must do more to counter these narratives. “We’re seeing patients who are not obese, who do not have diabetes, who are taking these drugs due to the fact that they want to seem like a certain influencer,” he said. “That’s a recipe for disaster when it comes to eating disorders.”
What Can Be Done?
As the use of GLP-1 agonists continues to grow, experts are calling for a multi-pronged approach to mitigate the risk of eating disorders:
- Stricter prescribing guidelines: The FDA and other regulatory bodies could update prescribing guidelines to include warnings about the risk of eating disorders, particularly for high-risk groups. Some clinicians are already advocating for mandatory mental health screenings before prescribing these drugs.
- Improved patient education: Patients need to be informed about the potential psychological side effects of GLP-1 agonists, including the risk of disordered eating. This education should come from healthcare providers, not social media influencers.
- Enhanced monitoring: Regular follow-ups with patients, including assessments for eating disorder symptoms, could help catch problems early. Digital tools, such as apps that track eating behaviors and mood, may also be useful.
- Research and funding: More studies are needed to understand the long-term psychological effects of GLP-1 agonists. Funding for this research should be a priority for public health agencies and pharmaceutical companies alike.
- Regulation of social media: Platforms like TikTok and Instagram could do more to limit the spread of misleading content about GLP-1 drugs. This could include fact-checking posts, adding disclaimers, or removing content that promotes off-label use.
Key Takeaways
- GLP-1 receptor agonists like semaglutide and tirzepatide are highly effective for weight loss and diabetes management, but emerging evidence suggests they may increase the risk of eating disorders in some patients.
- Adolescents, young adults, individuals with a history of eating disorders, and those with body image issues are particularly vulnerable.
- Social media trends and cultural pressures around weight loss are exacerbating the problem, with many patients using these drugs off-label for cosmetic purposes.
- Experts are calling for stricter prescribing guidelines, improved patient education, and enhanced monitoring to mitigate these risks.
- More research is needed to fully understand the psychological effects of GLP-1 agonists and to develop strategies for safe use.
The Road Ahead
The conversation around GLP-1 agonists and eating disorders is still in its early stages, but the stakes are high. As these drugs become a cornerstone of obesity and diabetes treatment, This proves crucial that clinicians, researchers, and policymakers work together to ensure they are used safely and responsibly. The next step will be a series of prospective studies, including a large-scale trial funded by the National Institutes of Health (NIH), which is set to begin later this year. The trial will track the psychological effects of GLP-1 agonists in over 10,000 patients over a five-year period.
In the meantime, patients and healthcare providers must remain vigilant. “These drugs are not a magic bullet,” said Dr. Gerke. “They have real benefits, but they also come with real risks. We need to treat them with the same caution we would any other powerful medication.”
For readers concerned about their own eating behaviors or those of a loved one, resources are available. The National Eating Disorders Association (NEDA) offers a helpline, screening tools, and educational materials. If you or someone you know is struggling, seek help from a qualified healthcare provider.
What are your thoughts on the potential risks of GLP-1 receptor agonists? Have you or someone you know experienced side effects related to these medications? Share your story in the comments below, and don’t forget to share this article with others who may be affected.